|
YPEL5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.12979999986752E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63783000000084E-05 |
| Normal-vs-Stage2 |
1.59842999999382E-05 |
| Normal-vs-Stage3 |
3.06709999620125E-08 |
| Normal-vs-Stage4 |
1.52369999950608E-08 |
| Stage1-vs-Stage2 |
6.833800E-02 |
| Stage1-vs-Stage3 |
8.703800E-02 |
| Stage1-vs-Stage4 |
1.954320E-02 |
| Stage2-vs-Stage3 |
5.972200E-01 |
| Stage2-vs-Stage4 |
9.862000E-01 |
| Stage3-vs-Stage4 |
4.822600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.75879999745277E-08 |
| Normal-vs-AfricanAmerican |
2.206200E-02 |
| Normal-vs-Asian |
1.155360E-04 |
| Caucasian-vs-AfricanAmerican |
2.601800E-01 |
| Caucasian-vs-Asian |
6.476400E-01 |
| AfricanAmerican-vs-Asian |
4.961800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.73690000346983E-08 |
| Normal-vs-Female |
4.27699999971942E-07 |
| Male-vs-Female |
6.334200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.13879999999556E-05 |
| Normal-vs-Age(41-60Yrs) |
6.88619999911211E-08 |
| Normal-vs-Age(61-80Yrs) |
1.60830004869439E-09 |
| Normal-vs-Age(81-100Yrs) |
1.543630E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.759980E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.844300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.896600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.348100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.862000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.479500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.286300E-02 |
| Classical-VS-Follicular |
1.422600E-03 |
| Classical-VS-Other |
3.233000E-01 |
| Classical-VS-Normal |
2.24070000000021E-05 |
| Tall-VS-Follicular |
7.113200E-01 |
| Tall-VS-Other |
9.560000E-01 |
| Tall-VS-Normal |
1.53400000002524E-06 |
| Follicular-VS-Other |
8.345800E-01 |
| Follicular-VS-Normal |
4.01830000384962E-08 |
| Other-VS-Normal |
7.001400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.37900002317571E-09 |
| Normal-vs-N1 |
3.54730000040604E-07 |
| N0-vs-N1 |
9.405000E-01 |
|
|
